Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1

D. Topalis, TC. Nogueira, T. De Schutter, C. El Amri, M. Krečmerová, L. Naesens, J. Balzarini, G. Andrei, R. Snoeck,

. 2016 ; 7 (9) : 10386-401.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000555

Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcinoma has been reported. No drug is approved for the treatment of HPV-related diseases but cidofovir (CDV) exhibits selective antiproliferative activity. In this study, we analyzed the effects of CDV-resistance (CDVR) in two HPV(+) (SiHaCDV and HeLaCDV) and one HPV(-) (HaCaTCDV) tumor cell lines. Quantification of CDV metabolites and analysis of the sensitivity profile to chemotherapeutics was performed. Transporters expression related to multidrug-resistance (MRP2, P-gp, BCRP) was also investigated. Alterations of CDV metabolism in SiHaCDV and HeLaCDV, but not in HaCaTCDV, emerged via impairment of UMP/CMPK1 activity. Mutations (P64T and R134M) as well as down-regulation of UMP/CMPK1 expression were observed in SiHaCDV and HeLaCDV, respectively. Altered transporters expression in SiHaCDV and/or HeLaCDV, but not in HaCaTCDV, was also noted. Taken together, these results indicate that CDVR in HPV(+) tumor cells is a multifactorial process.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000555
003      
CZ-PrNML
005      
20200121105922.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.7006 $2 doi
024    7_
$a 10.18632/oncotarget.7006 $2 doi
035    __
$a (PubMed)26824416
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Topalis, Dimitri $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
245    10
$a Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1 / $c D. Topalis, TC. Nogueira, T. De Schutter, C. El Amri, M. Krečmerová, L. Naesens, J. Balzarini, G. Andrei, R. Snoeck,
520    9_
$a Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcinoma has been reported. No drug is approved for the treatment of HPV-related diseases but cidofovir (CDV) exhibits selective antiproliferative activity. In this study, we analyzed the effects of CDV-resistance (CDVR) in two HPV(+) (SiHaCDV and HeLaCDV) and one HPV(-) (HaCaTCDV) tumor cell lines. Quantification of CDV metabolites and analysis of the sensitivity profile to chemotherapeutics was performed. Transporters expression related to multidrug-resistance (MRP2, P-gp, BCRP) was also investigated. Alterations of CDV metabolism in SiHaCDV and HeLaCDV, but not in HaCaTCDV, emerged via impairment of UMP/CMPK1 activity. Mutations (P64T and R134M) as well as down-regulation of UMP/CMPK1 expression were observed in SiHaCDV and HeLaCDV, respectively. Altered transporters expression in SiHaCDV and/or HeLaCDV, but not in HaCaTCDV, was also noted. Taken together, these results indicate that CDVR in HPV(+) tumor cells is a multifactorial process.
650    _2
$a ABC transportéry $x biosyntéza $7 D018528
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cytidintrifosfát $x biosyntéza $7 D003570
650    _2
$a cytosin $x analogy a deriváty $x farmakologie $7 D003596
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a nukleosidmonofosfátkinasa $x biosyntéza $x metabolismus $7 D009703
650    _2
$a organofosfonáty $x farmakologie $7 D063065
650    _2
$a Papillomaviridae $7 D027383
650    _2
$a infekce papilomavirem $x farmakoterapie $7 D030361
650    _2
$a fosforylace $7 D010766
650    _2
$a SLC transportéry $x biosyntéza $7 D000070590
650    _2
$a uridintrifosfát $x biosyntéza $7 D014544
650    _2
$a nádory děložního čípku $x farmakoterapie $x patologie $x virologie $7 D002583
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nogueira, Tatiane C $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
700    1_
$a De Schutter, Tim $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
700    1_
$a El Amri, Chahrazade $u Sorbonne Universités, UPMC University Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular and Functional Enzymology, Paris, France.
700    1_
$a Krečmerová, Marcela $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of The Czech Republic, v.v.i., Prague, Czech Republic.
700    1_
$a Naesens, Lieve $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
700    1_
$a Balzarini, Jan $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
700    1_
$a Andrei, Graciela $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. $7 gn_A_00006456
700    1_
$a Snoeck, Robert $u Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 9 (2016), s. 10386-401
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26824416 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20200121110259 $b ABA008
999    __
$a ok $b bmc $g 1179695 $s 961122
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 9 $d 10386-401 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options